The DOI matches its Crossref record; 99 of the 104 references it cites were found in a registry or an index.
Epigenetic gene silencing in cancer: the DNA hypermethylome
Open accessAbstract
Epigenetic gene inactivation in transformed cells involves many 'belts of silencing'. One of the best-known lesions of the malignant cell is the transcriptional repression of tumor-suppressor genes by promoter CpG island hypermethylation. We are in the process of completing the molecular dissection of the entire epigenetic machinery involved in methylation-associated silencing, such as DNA methyltransferases, methyl-CpG binding domain proteins, histone deacetylases, histone methyltransferases, histone demethylases and Polycomb proteins. The first indications are also starting to emerge about how the combination of cellular selection and targeted pathways leads to abnormal DNA methylation. One thing is certain already, promoter CpG island hypermethylation of tumor-suppressor genes is a common hallmark of all human cancers. It affects all cellular pathways with a tumor-type specific profile, and in addition to classical tumor-suppressor and DNA repair genes, it includes genes involved in premature aging and microRNAs with growth inhibitory functions. The importance of hypermethylation events is already in evidence at the bedside of cancer patients in the form of cancer detection markers and chemotherapy predictors, and in the approval of epigenetic drugs for the treatment of hematological malignancies. In the very near future, the synergy of candidate gene approaches and large-scale epigenomic technologies, such as methyl-DIP, will yield the complete DNA hypermethylome of cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, the epigenetic landscape of human malignancies exhibits massive reprogramming in their DNA methylation patterns.”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
MicroRNAs: small RNAs with a big role in gene regulation
He, L., & Hannon, G. J. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1379 · Cited by 7,118
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
RAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656
Epigenetic differences arise during the lifetime of monozygotic twins
Fraga, M. F., Ballestar, E., Paz, M. F., Ropero, S., Setien, F., Ballestar, M. L., Heine-Suñer, D., Cigudosa, J. C., Urioste, M., Benitez, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500398102 · Cited by 3,602
Self-citationmiR-15 and miR-16 induce apoptosis by targeting BCL2
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506654102 · Cited by 3,517
Cited by
Items 101–200 of 725
Casalino, L., & Verde, P. (2020) · Genes · doi:10.3390/genes11080922 · Cited by 91
“The tumor suppressor genes silenced by aberrant promoter hypermethylation encode a wide range of protein products, including cell cycle inhibitors (INK4A/p16 and Rb), DNA repair factors, detoxifying enzymes (GSTP1, glutathione S-transferase Pi 1), angiogenesis inhibitors (VHL, Von Hippel–Lindau tumor suppressor and TH…”
BackgroundKindlin 2 promotes breast cancer invasion via epigenetic silencing of the microRNA200 gene family
Yu, Y., Wu, J., Guan, L., Qi, L., Tang, Y., Ma, B., Zhan, J., Wang, Y., Fang, W., & Zhang, H. (2013) · International Journal of Cancer · doi:10.1002/ijc.28151 · Cited by 80
“Aberrant epigenetic modifications are involved in the downregulation of tumor suppressors in tumor development.(20) To scrutinize whether Kindlin 2 is involved in the epigenetic regulation of miR-200 family, the methylation of miR-200 family was examined upon Kindlin 2 overexpression or knockdown.”
BackgroundReactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors
Daskalakis, M., Brocks, D., Sheng, Y.-H., Islam, S., Ressnerova, A., Assenov, Y., Milde, T., Oehme, I., Witt, O., Goyal, A., et al. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1442623 · Cited by 93
“For example, DNA methylation of CGIs in promoter regions has been correlated with transcriptional repression [23].”
BackgroundEpidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy
Montalvo-Casimiro, M., González‐Barrios, R., Meraz-Rodríguez, M. A., Juárez-González, V. T., Arriaga-Canon, C., & Herrera, L. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605386 · Cited by 88
MiRNAs, epigenetics, and cancer
ROUHI, A. M., Mager, D. L., Humphries, R. K., & Kuchenbauer, F. C. (2008) · Mammalian Genome · doi:10.1007/s00335-008-9133-x · Cited by 90
“Approximately half of the human promoter regions contain CpG-rich regions (Bernstein et al. 2007) and therefore it is not surprising that the expression of miRNAs can be affected by promoter hypermethylation (Esteller 2007) or global hypomethylation (Jones and Baylin 2002).”
BackgroundChandola, U., Das, R., & Panda, B. (2014) · Briefings in Functional Genomics · doi:10.1093/bfgp/elu039 · Cited by 86
Heterochromatin protein 1α: a hallmark of cell proliferation relevant to clinical oncology
de Koning, L., Savignoni, A., Boumendil, C., Rehman, H., Asselain, B. J. R., Sastre‐Garau, X., & Almouzni, G. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900022 · Cited by 102
“Much effort has been put into the characterization of alterations in DNA methylation and different histone modifications (Esteller, 2007).”
BackgroundPromoter methylation and the detection of breast cancer
Brooks, J. D., Cairns, P., & Zeleniuch‐Jacquotte, A. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9415-y · Cited by 90
“This hypermethylation appears to be an early event in carcinogenesis [21, 24, 25], and occurs at least as frequently as genetic mutations in somatic cells so that hundreds of genes may be inactivated by DNA methylation in a single cancer [23, 26].”
BackgroundEpigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives
Singh, A., Gupta, S., & Sachan, M. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00182 · Cited by 90
“Promoter methylation mediated epigenetic silencing of gene is regulated by the recruitment of MBD (methyl CpG binding proteins such as MeCP2, MBD1, MBD2, and MBD4) which in turn regulates chromatin state by recruiting histone modifying and chromatin-remodeling complexes (repressors) at the site of methylation, which s…”
BackgroundRole of melatonin in the epigenetic regulation of breast cancer
Korkmaz, A., Sánchez‐Barceló, E. J., Tan, D., & Reiter, R. J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0103-5 · Cited by 86
Flatley, J. E., McNeir, K., Balasubramani, L., TIDY, J. A., Stuart, E. L., Young, T. A., & Powers, H. J. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0493 · Cited by 79
“Promoter hypermethylation of tumor suppressor genes is another recognized hallmark of human cancer (46).”
BackgroundWang, Z., & Yang, C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.002 · Cited by 84
“A common DNA methylation feature across almost all types of human cancer is the promoter CpG island hypermethylation of many tumor-suppressor genes [56].”
BackgroundDNA methylation biomarker candidates for early detection of colon cancer
Yi, J. M., Dhir, M., Guzzetta, A. A., Iacobuzio–Donahue, C. A., Heo, K., Yang, K., Suzuki, H., Toyota, M., Kim, H.-M., & Ahuja, N. (2012) · Tumor Biology · doi:10.1007/s13277-011-0302-2 · Cited by 83
“It has been well known that methylation of CpG islands in gene promoter regions is associated with aberrant silencing of transcription and is a mechanism for inactivation of tumor suppressor genes (p16, APC, Rb) from many other studies [4, 25].”
IQGAP1 and IQGAP2 are Reciprocally Altered in Hepatocellular Carcinoma
White, C. D., Khurana, H., Gnatenko, D. V., Li, Z., Odze, R. D., Sacks, D. B., & Schmidt, V. A. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-125 · Cited by 86
“Silencing of tumor suppressor genes by promoter hypermethylation is the most extensively studied epigenetic mechanism in tumorigenesis [41-43].”
BackgroundExpression profiling of DNA methylation-mediated epigenetic gene-silencing factors in breast cancer
Kar, S., Sengupta, D., Deb, M., Shilpi, A., Parbin, S., Rath, S. K., Pradhan, N., Rakshit, M., & Patra, S. K. (2014) · Clinical Epigenetics · doi:10.1186/1868-7083-6-20 · Cited by 79
“DNA methylation patterns are profoundly altered in malignant cells, characterized by paradoxical gene-specific regional hypermethylation and global hypomethylation of the genome [20,21].”
BackgroundDevelopment and validation of a CIMP-associated prognostic model for hepatocellular carcinoma
Li, G., Xu, W., Zhang, L., Liu, T., Jin, G.-N., Song, J., Wu, J., Wang, Y., Chen, W., Zhang, C., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.064 · Cited by 83
“Hypermethylation of promoter region is a crucial process that can lead to the epigenetic silencing of tumor suppressor genes [11,12].”
BackgroundHuang, K.-H., Huang, S., Chen, I., Liao, C., Wang, H., & Hsieh, L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2929 · Cited by 76
Epigenomics in cancer management
Costa, F. F. (2010) · Cancer Management and Research · doi:10.2147/cmr.s7280 · Cited by 83
Mayor, R., Casadomé, L., Azuara, D., Moreno, V. R., Clark, S. J., Capellá, G., & Peinado, M. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605045 · Cited by 76
Methylation Landscape of Human Breast Cancer Cells in Response to Dietary Compound Resveratrol
Medina‐Aguilar, R., Pérez‐Plasencia, C., Marchat, L. A., Gariglio, P., García-Mena, J., Cuevas, S. R., Ruíz‐García, E., la Vega, H. A., Juárez, J. H., Flores‐Pérez, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157866 · Cited by 81
The key culprit in the pathogenesis of systemic lupus erythematosus: Aberrant DNA methylation
Wu, H., Zhao, M., Tan, L., & Lu, Q. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.03.002 · Cited by 74
Kim, S. Y., Han, Y. K., Song, J. M., Lee, C. H., Kang, K., Yi, J. M., & Park, H. R. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0715-0 · Cited by 95
Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
Lodewijk, I., Nunes, S. P., Henrique, R., Jerónimo, C., Dueñas, M., & Paramio, J. M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01046-0 · Cited by 78
Thalhammer, A., Hansen, A. S., El-Sagheer, A. H., Brown, T., & Schofield, C. J. (2011) · Chemical Communications · doi:10.1039/c0cc05671e · Cited by 85
Smoking and microRNA dysregulation: a cancerous combination
Momi, N., Kaur, S., Rachagani, S., Ganti, A. K., & Batra, S. K. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.10.005 · Cited by 82
“Studies have reported promoter hypermethylation-mediated silencing of miRNAs in different cancers, including in acute lymphoblastic leukemia, breast cancer, colon cancer and prostate cancer [41] (Figure 3a).”
BackgroundGieni, R. S., & Hendzel, M. J. (2009) · Biochemistry and Cell Biology · doi:10.1139/o09-057 · Cited by 82
“These studies identified Polycomb-marked genes as major targets for DNMTs in cancer cells, leading to de novo methylation and stable gene silencing (Reynolds et al. 2006; Esteller 2007; Kondo et al. 2007; Schlesinger et al. 2007; Widschwendter et al. 2007).”
BackgroundInfluentialGenomic impact of cigarette smoke, with application to three smoking-related diseases
Talikka, M., Sierro, N., Ivanov, N. V., Chaudhary, N. I., Peck, M. J., Hoeng, J., Coggins, C. R. E., & Peitsch, M. C. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.725244 · Cited by 74
“In cancer biology, the most relevant, or at least the best understood, epigenetic mechanism refers to DNA hypermethylation of specific loci (CpG islands) in the promoter region of known and presumptive tumor suppressor genes which is a common hallmark of human tumors in general (Esteller, 2007), and of lung cancer in…”
BackgroundEpigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries
Wongtrakoongate, P. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i1.137 · Cited by 84
Synthetic epigenetics—towards intelligent control of epigenetic states and cell identity
Jurkowski, T. P., Ravichandran, M., & Stepper, P. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0044-x · Cited by 81
“Straightforward applications of these approaches for clinical studies could be, for example, to demethylate the promoters and thereby activate the expression of tumour suppressor genes, which are commonly silenced in cancer cells [117-120].”
BackgroundDiscovery of Candidate DNA Methylation Cancer Driver Genes
Pan, H., Renaud, L., Chaligné, R., Bloehdorn, J., Tausch, E., Mertens, D., Fink, A. M., Fischer, K., Zhang, C., Betel, D., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1334 · Cited by 77
“Promoter hypermethylation of TSGs has been surveyed across cancer in The Cancer Genome Atlas (TCGA) as well as other studies (1–3), and revealed that a plethora of cancer-related cellular pathways are disrupted by hypermethylation of TSG promoters, such as DNA repair (MLH1, RBBP8), cell cycle (CDKN2A, CDKN2B), p53 net…”
BackgroundPharmacologic Unmasking of Epigenetically Silenced Genes in Breast Cancer
Ostrow, K. L., Park, H. L., Hoque, M. O., Kim, M. S., Liu, J.-W., Argani, P., Westra, W. H., Criekinge, W. V., & Sidransky, D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1304 · Cited by 71
S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis
Martínez-Leal, J. F., Ferrer, I., Blanco‐Aparicio, C., Hernández‐Losa, J., y Cajal, S. R., Carnero, A., & LLeonart, M. E. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn198 · Cited by 75
Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives
Buociková, V., Ríos-Mondragón, I., Pilalis, E. D., Chatziioannou, A. A., Miklikova, S., Mego, M., Pajuste, K., Ruciņš, M., Yamani, N. E., Longhin, E., et al. (2020) · Cancers · doi:10.3390/cancers12123622 · Cited by 77
“MBD proteins interlink DNA methylation and histone modifications by engaging histone deacetylase complexes and chromatin remodeling factors, leading to chromatin condensation and thus to transcriptional repression [30].”
BackgroundLiggett, T., Melnikov, A. A., Marks, J. R., & Levenson, V. (2010) · International Journal of Cancer · doi:10.1002/ijc.25363 · Cited by 68
The three M’s: melanoma, microphthalmia‐associated transcription factor and microRNA
Bell, R. E., & Levy, C. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00931.x · Cited by 80
“The second major mechanism of miRNA dysregulation encompasses epigenetic alterations, which are associated with tumor progression (Esteller, 2007a).”
BackgroundPorcellini, E., Laprovitera, N., Riefolo, M., Ravaioli, M., Garajova, I., & Ferracin, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.049 · Cited by 66
DNA methylation/hydroxymethylation in melanoma
Fu, S., Wu, H., Zhang, H., Lian, C. G., & Lu, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.18293 · Cited by 71
“Methyl-CpG-binding domain (MBD) proteins, for example, can be recruited by methylated DNA; in turn, MBD family members recruit histone modifying and chromatin-remodeling complexes to the methylated sites [11].”
BackgroundGene-Specific Targeting of DNA Methylation in the Mammalian Genome
Urbano, A., Smith, J., Weeks, R. J., & Chatterjee, A. (2019) · Cancers · doi:10.3390/cancers11101515 · Cited by 72
Blood-based DNA methylation signatures in cancer: A systematic review
Li, Y., Fan, Z., Meng, Y., Liu, S., & Zhan, H. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166583 · Cited by 78
Haendler (2009) · International Journal of Oncology · doi:10.3892/ijo_00000406 · Cited by 73
DNA Methylation as Clinically Useful Biomarkers—Light at the End of the Tunnel
Levenson, V., & Melnikov, A. A. (2012) · Pharmaceuticals · doi:10.3390/ph5010094 · Cited by 68
“Methylation of promoter regions with high GC content (CpG islands, CGI) is probably the most direct mechanism of regulation, and higher methylation is associated with lower transcriptional activity [37–39].”
BackgroundRecent advances in salivary cancer diagnostics enabled by biosensors and bioelectronics
Mishra, S., Saadat-Moghaddam, D., Kwon, O., Lee, Y.-K., Choi, W., Kim, J., & Yeo, W. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2016.02.040 · Cited by 68
Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression
Ratovitski, E. A. (2017) · Current Genomics · doi:10.2174/1389202917666160803165229 · Cited by 70
“The main molecular events responsible for epigenetic regulation of gene expression are: DNA methylation, methylation and acetylation of chromatin histone and non-histone proteins, chromatin assembly and disassembly, and post-transcriptional gene regulation by non-coding RNAs [11-39].”
BackgroundInfluentialRhee, J., Kim, K., Chae, H., Evans, J. M., Yan, P. S., Zhang, B.-T., Gray, J. W., Spellman, P. T., Huang, T. H. ‐., Nephew, K. P., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt643 · Cited by 61
Epigenetic therapy as a novel approach in hepatocellular carcinoma
Anestopoulos, I., Voulgaridou, G.-P., Georgakilas, A. G., Franco, R., Pappa, A., & Panayiotidis, M. I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.005 · Cited by 65
Genome-wide DNA methylation profiling of non-small cell lung carcinomas
Carvalho, R. H., Haberle, V., Hou, J., van Gent, T., Thongjuea, S., van IJcken, W. F. J., Kockx, C. E. M., Brouwer, R. W. W., Rijkers, E., Sieuwerts, A. M., et al. (2012) · Epigenetics & Chromatin · doi:10.1186/1756-8935-5-9 · Cited by 60
“As previously reported by many groups [40-43], gene promoters are a target of methylation as an epigenetic regulatory mechanism.”
BackgroundEpigenetic Landscape of Liquid Biopsy in Colorectal Cancer
Rodríguez‐Casanova, A., Costa‐Fraga, N., Bao‐Caamano, A., López‐López, R., Muinelo‐Romay, L., & Díaz‐Lagares, Á. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.622459 · Cited by 62
“Importantly, the disruption of the epigenetic machinery has been proposed as a hallmark of cancer by several authors (Esteller, 2007; Bates, 2020).”
BackgroundRecurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation
Taioli, E., Ragin, C. C. R., Wang, X., Chen, J., Langevin, S. M., Brown, A. R., Gollin, S. M., GARTE, S. J., & Sobol, R. W. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-354 · Cited by 60
“Discussion Current research has shown that a number of tumor suppressor genes may be inactivated not only by genetic mechanisms such as deletions or point mutations, but also by hypermethylation or other similar epigenetic mechanisms [28] (see Table 1).”
BackgroundThe DNA methylome of glioblastoma multiforme
Martínez, R., & Esteller, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.12.030 · Cited by 68
“In general, densely methylated DNA is associated with deacetylated histones and compacted chromatin, which is refractory to transcription (Jones and Baylin, 2007; Esteller, 2007).”
BackgroundLee, Y. C. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1327 · Cited by 65
Hypermethylation in bladder cancer: biological pathways and translational applications
Sänchez‐Carbayo, M. (2012) · Tumor Biology · doi:10.1007/s13277-011-0310-2 · Cited by 59
“MBD family members in turn recruit histone-modifying and chromatin-remodeling complexes to methylated sites [9].”
BackgroundRodríguez‐Otero, P., Román‐Gómez, J., Vilas‐Zornoza, A., José‐Eneriz, E. S., Martín‐Palanco, V., Rifón, J., Torres, A., Calasanz, M. J., Agirre, X., & Prósper, F. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08812.x · Cited by 58
“In cancer, transcriptional silencing due to epigenetic modifications (CpG-island hypermethylation or histone modifications) is a crucial step in tumourigenesis and one of the main mechanisms of tumour-suppressor gene silencing (Esteller, 2007, 2008).”
BackgroundNew Insights into the Role of Exercise in Inhibiting mTOR Signaling in Triple‐Negative Breast Cancer
Agostini, D., Natalucci, V., Baldelli, G., Santi, M. D., Zeppa, S. D., Vallorani, L., Annibalini, G., Lucertini, F., Federici, A., Izzo, R., et al. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/5896786 · Cited by 64
“Emerging evidence points to epigenetic silencing by hypermethylation as a possible mechanism through which these tumor suppressor/growth inhibitor miRNAs are downregulated in TNBC [55].”
BackgroundWasenang, W., Chaiyarit, P., Proungvitaya, S., & Limpaiboon, T. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0634-0 · Cited by 62
Spurling, C. C., Suhl, J. A., Boucher, N., Nelson, C. E., Rosenberg, D. W., & Giardina, C. A. (2008) · Nutrition and Cancer · doi:10.1080/01635580802008278 · Cited by 62
“Aging and cancer may also result in the hypermethylation of CpG islands associated with gene promoters (50).”
BackgroundChen, L., Ma, Y., Kim, E. Y., Yu, W., Schwartz, R. J., Qian, L. M., & Wang, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031005 · Cited by 67
“The PRC mainly catalyzes trimethylation of H3 lysine 27 (H3K27Me3) for gene silencing, whereas the TrxG complexes catalyzes trimethylation of H3 lysine 4 (H3K4Me3) for activation; both groups preferentially target the histone 3 on CpG islands that are present in the cis-regulatory region of a broad spectrum of genes […”
BackgroundAl-Romaih, K. I., Sadiković, B., Yoshimoto, M., Wang, Y. Z., Zieleńska, M., & Squire, J. A. (2008) · Neoplasia · doi:10.1593/neo.08174 · Cited by 62
“that are present in the promoters and span exonic and intronic regions at many loci throughout the human genome [7].”
BackgroundEpigenetics and the control of epithelial sodium channel expression in collecting duct
Zhang, D., Yu, Z.-Y., Cruz, P. E., Kong, Q., Li, S., & Kone, B. C. (2008) · Kidney International · doi:10.1038/ki.2008.475 · Cited by 66
“’ Methylation patterns of CpG islands are essential for gene expression: tissue-specific gene expression is partly related to different methylation patterns of CpG islands, and aberrant CpG island methylation patterns are often found in tumors.(4) DNA methylation is typically involved in transcriptional silencing (Fig…”
Zare, M., Jazii, F. R., Alivand, M. R., Nasseri, N. K., Malekzadeh, R., & Yazdanbod, M. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-24 · Cited by 59
Promoter hypermethylation and expression profile of MGMT and CDH1 genes in oral cavity cancer
Kordi-Tamandani, D. M., Moazeni‐Roodi, A., Rigi‐Ladiz, M. A., Hashemi, M. M., Birjandian, E., & Torkamanzehi, A. (2010) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2010.06.017 · Cited by 57
Wilczyński, J. R., Wilczyński, M., & Paradowska, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052496 · Cited by 65
Brevet, M., Fucks, D., Chatelain, D., Regimbeau, J., Delcenserie, R., Sevestre, H., & Ouadid‐Ahidouch, H. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181a56ebf · Cited by 65
Li, S., Xue, L., Wang, M., Qiang, P., Xu, H., Zhang, X., Kang, W., You, F., Xu, H., Wang, Y., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s198567 · Cited by 64
Back and forth in time: Directing age in iPSC-derived lineages
Cornacchia, D., & Studer, L. (2017) · Brain Research · doi:10.1016/j.brainres.2015.11.013 · Cited by 56
Glen, A., Evans, C. A., Gan, C. S., Cross, S. S., Hamdy, F. C., Gibbins, J. M., Down, J. M., Eaton, C. L., Noirel, J., Wright, P. C., et al. (2010) · The Prostate · doi:10.1002/pros.21167 · Cited by 57
“Increased DNA methylation (hyper-methylation) occurring at CpG sites within the promoter region or the first exon of a gene is a common epigenetic alteration seen in human cancers and is associated with transcriptional silencing [43,44].”
BackgroundIdentification of Novel Methylation Markers in Hepatocellular Carcinoma using a Methylation Array
Shin, S. H., Kim, B., Jang, J., Suh, K., & Kang, G. H. (2010) · Journal of Korean Medical Science · doi:10.3346/jkms.2010.25.8.1152 · Cited by 61
“However, in association with carcinogenesis, hundreds of promoter CpG islands undergo aberrant hypermethylation, which represses gene transcription of active genes or enforces suppression of already inactive genes (5).”
BackgroundBenton, G., Crooke, E., & George, J. (2009) · The FASEB Journal · doi:10.1096/fj.08-128702 · Cited by 57
“in many other tumor suppressor genes (15), acting as a”
BackgroundNew insights into mechanisms that regulate DNA methylation patterning
Ficz, G. (2015) · Journal of Experimental Biology · doi:10.1242/jeb.107961 · Cited by 55
“…differentiate into neuronal progenitor cells (Mohn et al., 2008), hypermethylation of CGI promoters is observed at higher frequency in cancer and during ageing (Esteller, 2007; Issa, 2003), and opinions are divided as to whether this is a general mechanism in normal development (Bestor, 2000).”
BackgroundStrategies to overcome tumour relapse caused by antigen escape after CAR T therapy
Lu, Y., & Fu, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02334-6 · Cited by 67
“Aberrant hypermethylation occurring in lymphoma patients and their cell lines, which is often located on CpG island within the promoter region of tumour suppressor gene, can lead to the silencing of the gene [45].”
DNA modifications in atherosclerosis: From the past to the future
Borghini, A., Cervelli, T., Galli, A., & Andreassi, M. G. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.038 · Cited by 58
“CpG islands are associated with promoter regulatory regions of almost all housekeeping genes as well as with approximately half of tissue-specific genes [65].”
BackgroundZhang, B., Xing, X., Li, J., Lowdon, R. F., Zhou, Y., Lin, N., Zhang, B., Sundaram, V., Chiappinelli, K. B., Hagemann, I. S., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-868 · Cited by 58
“Hypermethylation of CGIs, especially those associated with tumor suppressor genes, is considered a hallmark of many types of cancers [39,40].”
BackgroundLong non-coding RNAs involved in metastasis of gastric cancer
Lin, M.-T., Song, H., & Ding, X. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i33.3724 · Cited by 53
Huisman, C., van der Wijst, M. G. P., Schokker, M., Blancafort, P., Terpstra, M. M., Kok, K., van der Zee, A. G. J., Schuuring, E. M. D., Wisman, G. B. A., & Rots, M. G. (2015) · Molecular Therapy · doi:10.1038/mt.2015.226 · Cited by 54
Epigenetic and Copy Number Variation Analysis in Retinoblastoma by MS-MLPA
Livide, G., Epistolato, M. C., Amenduni, M., Disciglio, V., Marozza, A., Mencarelli, M. A., Toti, P., Lazzi, S., Hadjistilianou, T., Francesco, S. D., et al. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9498-8 · Cited by 56
“The advancement acquired in knowledge of gene expression regulation by epigenetic changes is improving our learning of tumor onset and development [23–25].”
BackgroundDNA methylation changes in cells regrowing after fractioned ionizing radiation
Kuhmann, C., Weichenhan, D., Rehli, M., Plass, C., Schmezer, P., & Popanda, O. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.048 · Cited by 54
“For example, hypermethylation in CpG rich regulatory regions can result in transcriptional inactivation of tumor suppressor genes in carcinogenesis [1].”
BackgroundLauss, M., Aine, M., Sjödahl, G., Veerla, S., Patschan, O., Guðjónsson, S., Chebil, G., Lövgren, K., Fernö, M., Månsson, W., et al. (2012) · Epigenetics · doi:10.4161/epi.20837 · Cited by 53
“Epigenetic changes by DNA methylation at CG dinucleotide sites (CpGs) are frequent events in tumor development.(8,9) Initially, DNA methylation studies were limited to 5' promoter regions of a small number of genes.”
BackgroundBarbano, R., Pasculli, B., Rendina, M., Fontana, A., Fusilli, C., Copetti, M., Castellana, S., Valori, V., Morritti, M., Graziano, P., et al. (2017) · Scientific Reports · doi:10.1038/srep45283 · Cited by 52
Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
Mrakovcic, M., Kleinheinz, J., & Fröhlich, L. F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091883 · Cited by 55
“A principal hallmark of tumorigenesis and cancer progression are (epi)genetic changes resulting in disruption of crucial cell signaling pathways and cellular processes that are characterized by uncontrolled proliferation [1,62,63].”
BackgroundUncovering the DNA methylome in chronic lymphocytic leukemia
Cahill, N., & Rosenquist, R. (2013) · Epigenetics · doi:10.4161/epi.23439 · Cited by 52
“DNA methylation is also recognized as a relatively stable modification inducing transcriptional inactivation of both protein coding and non-coding regulatory miRNAs.(2,6,7) For this reason, DNA methylation is now considered one of the hallmark mechanisms of aberrant gene silencing in cancer.”
BackgroundDNA methylation in neurodegenerative disorders: a missing link between genome and environment?
Iraola‐Guzmán, S., Estivill, X., & Rabionet, R. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01673.x · Cited by 57
“Finally, another function for DNA methylation is linked to the hypermethylation of repetitive elements, protecting the genome from reactivation of endoparasitic sequences, and preventing chromosomal instability, translocations, and gene disruption (99, 108, 109).”
BackgroundShin, D. Y., Kang, H. S., Kim, G., Kim, W., Yoo, Y. H., & Choi, Y. H. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.01.004 · Cited by 54
“However, in tumor cells, aberrant region-specific hypermethylation of CpG islands located in or near gene promoters is associated with transcriptional silencing [6,7].”
BackgroundRose, M., Gaisa, N. T., Antony, P., Fiedler, D., Heidenreich, A., Otto, W., Denzinger, S., Bertz, S., Hartmann, A., Karl, A., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt375 · Cited by 52
Schutter, H. D., Kimpe, M., Isebaert, S. F., & Nuyts, S. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.032 · Cited by 52
Ruiz-Magaña, M. J., Martínez-Aguilar, R., Lucendo, E., Campillo-Davó, D., Schulze‐Osthoff, K., & Ruiz‐Ruiz, C. (2016) · Oncotarget · doi:10.18632/oncotarget.7871 · Cited by 53
“In particular, silencing of tumor suppressor genes by promoter hypermethylation has been described in a variety of human solid tumors such as lung, colorectal, breast, gastric, endometrial and bladder tumors, as well as in hematopoietic malignancies [1-3], contributing to clonal expansion of malignant cells.”
BackgroundKobets, T., & Williams, G. M. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.11.011 · Cited by 53
Singh, P., Bhadada, S. K., Dahiya, D., Arya, A. K., Saikia, U. N., Sachdeva, N. K., Kaur, J., Brandi, M. L., & Rao, S. D. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa419 · Cited by 51
“Previous studies have emphasized the role of promoter DNA methylation in the reduction of CaSR expression in colon cancer and neuroblastoma (13, 28).”
BackgroundPhua, Y. W., Nguyen, A., Roden, D. L., Elsworth, B., Deng, N., Nikolić, I., Yang, J., McFarland, A., Russell, R., Kaplan, W. H., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0593-0 · Cited by 55
“There is emerging evidence for epigenetic silencing by hypermethylation [48] of miRNAs with tumour suppressor properties or growth inhibitory functions in various malignancies [49–52].”
BackgroundRodríguez-Miguel, C., Moral, R., Escrich, R., Vela, E., Solanas, M., & Escrich, E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138980 · Cited by 50
“Hypermethylation of CpG islands in the promoter regions of tumor suppressor genes is one of the main mechanisms for gene silencing [34].”
BackgroundSystems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma
Pradhan, M. P., Desai, A., & Palakal, M. J. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-141 · Cited by 52
“Earlier studies have reported chromosome 6 and 15 to play an important role in lung cancer [84,85] also certain chromosomal regions were more hypermethylated [15].”
BackgroundTargeting histone deacetylases for the treatment of disease
Lawless, M. W., Norris, S., O'Byrne, K. J., & Gray, S. G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00571.x · Cited by 53
“Aberrant epigenetic modifications are a frequent hallmark of cancer and include both DNA CpG methylation [71], and histone posttranslational modifications [72].”
BackgroundIbrahim, N., He, L., Leong, C.-O., Xing, D., Karlan, B. Y., Swisher, E. M., Rueda, B. R., Oršulić, S., & Ellisen, L. W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0668 · Cited by 54
Wiesmann, F., Veeck, J., Galm, O., Hartmann, A., Esteller, M., Knüchel, R., & Dahl, E. (2009) · Breast Cancer Research · doi:10.1186/bcr2319 · Cited by 50
“Methylation of the EDN3 promoter in breast cancer cell lines Since promoter hypermethylation is responsible for transcriptional silencing of important tumour suppressor genes in various human cancer types [30], we searched all three EDN genes for the presence of CpG islands in their promoter region.”
BackgroundNuyts (2009) · Oncology Reports · doi:10.3892/or_00000251 · Cited by 50
Mahalingam, D., Kong, C. M., Lai, J. K. H., Tay, L. L., Yang, H. H., & Wang, X. (2012) · Scientific Reports · doi:10.1038/srep00592 · Cited by 54
DFNA5promoter methylation a marker for breast tumorigenesis
Croes, L., de Beeck, K. O., Pauwels, P., Berghe, W. V., Peeters, M., Fransén, E., & Camp, G. V. (2017) · Oncotarget · doi:10.18632/oncotarget.16654 · Cited by 49
Culture-induced recurrent epigenetic aberrations in human pluripotent stem cells
Weissbein, U., Plotnik, O., Vershkov, D., & Benvenisty, N. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006979 · Cited by 51
DNA methylation regulated microRNAs in human cervical cancer
Varghese, V. K., Shukla, V., Kabekkodu, S. P., Pandey, D., & Satyamoorthy, K. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22761 · Cited by 51
Oliveira, K. C. D. S., Araújo, T. M. T., Albuquerque, C. I., Barata, G. A., Gigek, C. O., Leal, M. F., Wisnieski, F., Mello, F. A. R., Khayat, A. S., de Assumpção, P. P., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i35.7951 · Cited by 54
Epigenetic Regulation of Cancer Stem Cells by the Aryl Hydrocarbon Receptor Pathway
Akhtar, S., Hourani, S., Therachiyil, L., Al‐Dhfyan, A., Agouni, A., Zeidan, A., Shahab Uddin, M. S., & Korashy, H. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.014 · Cited by 56
Epigenetic Regulations of Microglia/Macrophage Polarization in Ischemic Stroke
Qiu, M., Xu, E., & Zhan, L. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.697416 · Cited by 49
“Further, the H19 gene knockout inhibited the activation of M1-like microglia but promoted the polarization of M2-like microglia in BV2 cells after OGD (Wang et al., 2017b).”
BackgroundInfluential
Metadata
- Authors
- Esteller, M.
- Affiliations
- Spanish National Cancer Research Centre (ES)
- Corresponding author
- Esteller, Manel
- ORCID
- Esteller, Manel
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-04-15
- Volume
- 16
- Issue
- R1
- Pages
- R50-R59
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2158207797
- Cited by
- 725
- References
- 104
- Citations by year
- 2026: 12 · 2025: 24 · 2024: 17 · 2023: 34 · 2022: 35 · 2021: 29 · 2020: 17 · 2019: 35 · 2018: 38 · 2017: 44 · 2016: 45 · 2015: 56 · 2014: 36 · 2013: 56 · 2012: 62
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Syndromes and Imprinting
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Keywords
- epigenetic silencing, DNA hypermethylation, methylome, tumor suppressor, DNA methyltransferases, methyl-CpG binding domain proteins, histone deacetylase, histone methyltransferase, histone demethylase, Polycomb group proteins, DNA repair genes, microRNA, tumor markers, chemotherapy response prediction, epigenetic drugs, hematologic malignancies
- MeSH terms
- Werner Syndrome Helicase, Aging, Exodeoxyribonucleases, Humans, Neoplasms, RNA, Neoplasm, Werner Syndrome, Genes, Tumor Suppressor, CpG Islands, DNA Methylation, Gene Silencing, MicroRNAs, Epigenesis, Genetic, RecQ Helicases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.